Skip to main content

TCR2 Therapeutics Inc.

TCRRDelisted Jun 1, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001750019

TCR2 Therapeutics Inc. was delisted on Jun 1, 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.5M in total; no superinvestor held it.

Holders of 5% or more of TCRR

Holders whose latest Schedule 13D or 13G filing reports 5% or more of TCR2 Therapeutics Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of TCR2 Therapeutics Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

15 Schedule 13D and 13G filings on TCR2 Therapeutics Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on TCRR
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2024Tang Capital Partners LP13G/AOld format–––SEC
May 5, 2023Tang Capital Partners LP13G/AOld format–––SEC
Feb 14, 2023Tang Capital Partners LP13G/AOld format–––SEC
Feb 9, 2023K2 Principal Fund, L.P.13G/AOld format–––SEC
Sep 1, 2022K2 Principal Fund, L.P.13GOld format–New–SEC
Jul 8, 20224:57 PM ETBlackRock Inc.13GOld format–––SEC
Mar 4, 2022Tang Capital Partners LP13GOld format–New–SEC
Feb 14, 2022Redmile Group, LLC13G/AOld format–––SEC
Feb 3, 20224:41 PM ETBlackRock Inc.13G/AOld format–––SEC
Nov 10, 2021Wellington Management Group LLP13G/AOld format–––SEC
Feb 16, 2021ArrowMark Colorado Holdings LLC13G/AOld format–––SEC
Feb 16, 2021Redmile Group, LLC13G/AOld format–––SEC
Feb 9, 2021Upnorth Investment Ltd13G/AOld format–––SEC
Feb 2, 20212:56 PM ETBlackRock Inc.13GOld format–New–SEC
Jan 11, 2021Wellington Management Group LLP13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell TCR2 Therapeutics Inc. shares.

No Form 144 notices for TCR2 Therapeutics Inc. are on file.